Use of PET and MRI imaging facilities, plus [11C] radiopharmaceuticals at Invicro LLC

GoodsAward procedure without prior publication of a call for competition

Awarded value£1,883,380published contract · exc. VAT

Awarded 13 Oct 2022no call for competition

Awarded to Imanova

What is being bought

Published requirement description

PET and MRI scanning, radioligand production, and biomarker analysis

CPV: Medical solutions

single lot · no lot value published

Lot #1PET and MRI scanning, radioligand production, and biomarker analysisAwarded

PET and MRI scanning, radioligand production, and biomarker analysis

Only UK provider of PET tracers [11C]BU90008, [11C]SA4503, and [18F]BCPP-EF, that are currently used for our studies.
Invicro is located within the Hammersmith Hospital Campus, its location accommodates research participants for image and clinical assessments without increased burden and travel for the participants. While also reducing cost and time to conduct the studies.
[11C] tracers (with short half-life of about 20 minutes) and of [18F] radiotracers (with half-life of about 120 minutes) are produced in house and the short half-life of the [11C] tracers means Invicro’s two in-house cyclotron’s must be used. Their radioligand development platform means implementation of new tracers is not available at other facilities.
Invicro has the equipment and facilities to collect arterial blood samples during the scans and analyze the quantity of the radioactive metabolites on site.

Delivery: South West

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 21 Oct 2022, 10:52 BST
Last source update: 21 Oct 2022, 10:52 BST
Authority reference: UOE/2022/064/SB
FTS notice number: 2022/S 000-029714
Classification (CPV): Medical solutions
Delivery area: South West (UKK4)
Official registry OCID: ocds-h6vhtk-0377ba Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: The research conducted by the Neurodegeneration Imaging Group requires the use of [11C] radiopharmaceutical, as well as an imaging facility that can provide PET-MR scanners with accompanying arterial line capabilities. Due to the very short half-life of the the [11C] tracers, these research studies are limited to facilities that have an in-house cyclotron. Imanova, trading as Invicro, not only has the in-house production of the [11C] tracers, which have a short half-life of approximately 20 minutes and the [18F] radiotracers with a half-life of approximately 120 minutes, they also host two cyclotrons on site. This coupled with the research facility’s location in London, where participants who are participating in the study have clinics has resulted in, for technical reasons, only Invicro being able to provide the tracers and in-house service to deliver the research outputs at present.

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £1,883,3801 contract exc. VAT

Bids received 1

Contracts signed 1latest 13 Oct 2022

Awarded to	Value	Date	Status
ImanovaSMETBC	£1,883,380 †	—	Awarded

Contracts

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authorityEducationBody governed by public lawEducation RC000653 Northcote House, Exeter, South West, EX4 4QHContact name, email, phone

Dispute resolution & review bodies

1 commercial party on the notice

Official links; attachments are not copied

No document links were published on the notice.